Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494488 · ClinicalTrials.gov registry record · Early Phase 1
Differential Thrombogenesis by EPA and DHA Mediated by HDL
A Early Phase 1 study of Hypertriglyceridemia and Lipid Metabolism Disorders, sponsored by The Miriam Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06494488: Recruiting Early Phase 1 study of Hypertriglyceridemia and Lipid Metabolism Disorders, sponsored by The Miriam Hospital.
NCT06494488 is a Early Phase 1 study of Hypertriglyceridemia and Lipid Metabolism Disorders that is actively recruiting participants, run by The Miriam Hospital. The registered enrollment target is 80 participants, below the 173-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06494488, a Early Phase 1 study of Hypertriglyceridemia and Lipid Metabolism Disorders, is actively recruiting participants, sponsored by The Miriam Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels. The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Participants will: Visit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.
Primary Outcome
Platelet aggregation will be assessed as the primary endpoint. The percentage of platelet aggregation will be measured at multiple time points, and the area under the curve (AUC) will be calculated to serve as a comprehensive marker of platelet aggregation response. Data will be presented as mean ± standard deviation or other appropriate statistical summaries.
Conditions Studied
Interventions
- DRUG EPA
- DRUG DHA
Study Locations (1)
Rhode Island
- Brown University Health - Lipid Clinic - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2028-03-31 |
| Phase | Early Phase 1 |
What NCT06494488 shows while recruiting
NCT06494488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 173-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which EPA is the first listed.
NCT06494488 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06494488 about?
NCT06494488 is a clinical study titled "Differential Thrombogenesis by EPA and DHA Mediated by HDL". The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels. The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoi...
What is the current status of trial NCT06494488?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2025-07-10. Estimated completion is 2028-03-31.
What conditions does trial NCT06494488 study?
This clinical trial studies the following conditions: Hypertriglyceridemia, Lipid Metabolism Disorders.
What interventions are being tested in trial NCT06494488?
The interventions under investigation include: EPA (DRUG), DHA (DRUG).
Who is sponsoring clinical trial NCT06494488?
This trial is sponsored by The Miriam Hospital, which has 136 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06494488 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06494488's enrollment target sits among peer trials
80 11th of 25 higher than 15 of 25 other Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
RECRUITING · Phase 3
-
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
RECRUITING · Phase 2
-
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
ACTIVE NOT RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI